Noninvasive prenatal diagnosis of Mendelian disorders for consanguineous couples by relative genotype dosage

Clin Genet. 2023 Nov;104(5):505-515. doi: 10.1111/cge.14399. Epub 2023 Jul 12.

Abstract

Noninvasive prenatal diagnosis relies on the presence in maternal blood of circulating cell-free fetal DNA released by apoptotic trophoblast cells. Widely used for aneuploidy screening, it can also be applied to monogenic diseases (NIPD-M) in case of known parental mutations. Due to the confounding effect of maternal DNA, detection of maternal or biparental mutations requires relative haplotype dosage (RHDO), a method relying on the presence of SNPs that are heterozygous in one parent and homozygous in the other. Unavoidably, there is a risk of test failure by lack of such informative SNPs, an event particularly likely for consanguineous couples who often share common haplotypes in regions of identity-by-descent. Here we present a novel approach, relative genotype dosage (RGDO) that bypasses this predicament by directly assessing fetal genotype with SNPs that are heterozygous in both parents (frequent in regions of identity-by-descent). We show that RGDO is as sensitive as RHDO and that it performs well over a large range of fetal fractions and DNA amounts, thereby opening NIPD-M to most consanguineous couples. We also report examples of couples, consanguineous or not, where combining RGDO and RHDO allowed a diagnosis that would not have been possible with only one approach.

Keywords: cell-free circulating DNA; consanguinity; fetal DNA; monogenic disease; noninvasive prenatal diagnosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Consanguinity
  • DNA / genetics
  • Female
  • Genotype
  • Humans
  • Noninvasive Prenatal Testing*
  • Pregnancy
  • Prenatal Diagnosis / methods

Substances

  • DNA